Skip to main content

Table 1 Sociodemographic and clinical features of symptomatic SARS-CoV-2 positive children and adolescentsa diagnosed between 3/12/2020 and 9/28/2020b (n = 1000 unless otherwise specified)

From: The first 1000 symptomatic pediatric SARS-CoV-2 infections in an integrated health care system: a prospective cohort study

Characteristic or clinical variable

No. (%)

Age (y), median, IQR

14.0 (7.2–17.3)

Range

0.04–22.8

Age groups

 <1 year

87 (9)

 1–4 years

99 (10)

 5–9 years

140 (14)

 10–14 years

230 (23)

 ≥15 years

444 (44)

Gender, female

523 (52.3)

Racec

 White

789 (78.9)

 Black

129 (12.9)

 Asian

45 (4.5)

 Multiracial

72 (7.2)

 Other or Unknown

19 (1.9)

Hispanic ethnicity

203 (20.3)

Testing location

 Outpatient clinic or testing site

801 (80.1)

 Emergency department

197 (19.7)

 Hospital admission

2 (0.2)

Method of data collection

 Patient interview

237 (23.7 %)

 Medical record review

839 (83.9 %)

SARS-CoV-2 exposure

 Known household contact with COVID-19

409 (40.9)

 Known community contact with COVID-19

241 (24.1)

Days to return test results (mean ± SD)

1.1 ± 1.3

 Median (range)

1.0 (0–17)

Any comorbidity

177 (17.7)

Chronic lung disease

77 (7.7)

Neurologic condition

33 (3.3)

Cardiovascular disease

27 (2.7)

Diabetes mellitus

10 (1.0)

Immunocompromising condition

9 (0.9)

Chronic renal disease

8 (0.8)

Other chronic condition

65 (6.5)

Body mass index, median (IQR), n = 572

20.3 (17.1–23.8)

Underweight (BMI < 18.5)

165 (28.8)

Normal weight (BMI 18.5–24.9)

280 (49.0)

Overweight (BMI 25-29.9)

75 (13.1)

Obese (BMI ≥ 30)

52 (9.1)

Symptom resolution at early follow-up (n = 892)

398 (44.6)

Symptom resolution at later follow-up (n = 471)

443 (94.0)

Outcomes

 Hospitalization

  Remained outpatient

959 (95.9)

  Admitted to hospital

41 (4.1)

 ICU admission

8 (0.8)

 Mechanical ventilation

2 (0.2)

 Prescribed remdesivir

9 (0.9)

Death4

1 (0.1)

 Clinical symptoms

  Headache

424 (42.4)

  Sore throat

361 (36.1)

  Fever > 100.4 F (38.0 C)

337 (33.7)

  Nausea or vomiting

147 (14.7)

  Shortness of breath (dyspnea)

98 (9.8)

  Abdominal pain

82 (8.2)

  Vomiting

16 (1.6)

  Hypoxia

12 (1.2)

  1. aCohort includes 995 individuals < = 18 years of age and 5 individuals 19 and older who received long-term primary and subspecialty care in the pediatric facility (age range 19–22)
  2. bIncludes 1 infant who developed symptoms and positive SARS-CoV-2 test at 5 weeks of age after being born to mother who was SARS-CoV-2 positive at time of delivery
  3. cTotal n > 1000 as several subjects reported association with more than one race category
  4. dCause of death not definitively associated with SARS-CoV-2 infection in patient with multiple comorbidities
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us